

# Daniela Pietra

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5542532/publications.pdf>

Version: 2024-02-01

115  
papers

10,382  
citations

47006

47  
h-index

32842

100  
g-index

117  
all docs

117  
docs citations

117  
times ranked

7187  
citing authors

#	ARTICLE	IF	CITATIONS
1	Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms. <i>Blood</i> , 2022, 139, 2716-2720.	1.4	3
2	Type I but Not Type II Calreticulin Mutations Activate the IRE1 $\pm$ /XBP1 Pathway of the Unfolded Protein Response to Drive Myeloproliferative Neoplasms. <i>Blood Cancer Discovery</i> , 2022, 3, 298-315.	5.0	12
3	Platelet count predicts driver mutations <sup>TM</sup> co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis. <i>Leukemia</i> , 2021, 35, 1490-1493.	7.2	5
4	Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms. <i>Leukemia</i> , 2021, 35, 2371-2381.	7.2	17
5	Systemic mastocytosis and lymphoplasmacytic lymphoma: an unusual and intriguing form of SM-AHN. <i>Leukemia and Lymphoma</i> , 2021, 62, 1782-1785.	1.3	0
6	Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis. <i>Blood Advances</i> , 2021, 5, 1452-1462.	5.2	8
7	Enrichment of Double RUNX1 Mutations in Acute Leukemias of Ambiguous Lineage. <i>Frontiers in Oncology</i> , 2021, 11, 726637.	2.8	3
8	The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8885.	4.1	13
9	Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning. <i>Blood</i> , 2020, 135, 287-292.	1.4	34
10	Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms. <i>Blood</i> , 2020, 135, 133-144.	1.4	52
11	Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. <i>Cancer Medicine</i> , 2019, 8, 4089-4092.	2.8	16
12	Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms. <i>Blood</i> , 2019, 134, 199-210.	1.4	54
13	Ruxolitinib treatment and risk of B $\bar{c}$ cell lymphomas in myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2019, 94, E185-E188.	4.1	26
14	Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. <i>Haematologica</i> , 2018, 103, e392-e394.	3.5	31
15	Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. <i>Leukemia Research</i> , 2018, 69, 100-102.	0.8	13
16	Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. <i>Blood Cancer Journal</i> , 2018, 8, 89.	6.2	13
17	Diagnosis and management of prefibrotic myelofibrosis. <i>Expert Review of Hematology</i> , 2018, 11, 537-545.	2.2	13
18	Clinical significance of somatic mutation in unexplained blood cytopenia. <i>Blood</i> , 2017, 129, 3371-3378.	1.4	379

#	ARTICLE	IF	CITATIONS
19	Recommendations for molecular testing in classical Ph1-neg myeloproliferative disordersâ€”A consensus project of the Italian Society of Hematology. <i>Leukemia Research</i> , 2017, 58, 63-72.	0.8	25
20	A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. <i>Leukemia</i> , 2017, 31, 2726-2731.	7.2	242
21	Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. <i>Blood</i> , 2017, 129, 3227-3236.	1.4	137
22	CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles. <i>Blood Cancer Journal</i> , 2017, 7, 638.	6.2	27
23	Driver mutationsâ€™™ effect in secondary myelofibrosis: an international multicenter study based on 781 patients. <i>Leukemia</i> , 2017, 31, 970-973.	7.2	41
24	Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. <i>Oncotarget</i> , 2017, 8, 101735-101744.	1.8	45
25	Sequential evaluation of <i>CALR</i> mutant burden in patients with myeloproliferative neoplasms. <i>Oncotarget</i> , 2017, 8, 33416-33421.	1.8	7
26	Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. <i>American Journal of Hematology</i> , 2016, 91, 918-922.	4.1	47
27	Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. <i>Blood</i> , 2016, 127, 325-332.	1.4	228
28	Germline RBBP6 mutations in familial myeloproliferative neoplasms. <i>Blood</i> , 2016, 127, 362-365.	1.4	49
29	LNK mutations in familial myeloproliferative neoplasms. <i>Blood</i> , 2016, 128, 144-145.	1.4	36
30	Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group. <i>American Journal of Hematology</i> , 2016, 91, 681-686.	4.1	80
31	Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary myelofibrosis. <i>International Journal of Cancer</i> , 2016, 138, 1657-1669.	5.1	6
32	Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. <i>Leukemia</i> , 2016, 30, 431-438.	7.2	216
33	Differences in Clinical and Molecular Characteristics and Outcome in Prefibrotic and Overt Primary Myelofibrosis According to 2016 WHO Criteria. a Study on 639 Patients of the Agimm Group. <i>Blood</i> , 2016, 128, 943-943.	1.4	1
34	Impact of mutational status on pregnancy outcome in patients with essential thrombocythemia. <i>Haematologica</i> , 2015, 100, e443-e445.	3.5	30
35	Allelic imbalance in CALR somatic mutagenesis. <i>Leukemia</i> , 2015, 29, 1431-1435.	7.2	5
36	SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. <i>Blood</i> , 2015, 126, 233-241.	1.4	361

#	ARTICLE	IF	CITATIONS
37	Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene. <i>Annals of Hematology</i> , 2015, 94, 1927-1928.	1.8	51
38	Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. <i>Leukemia</i> , 2015, 29, 66-75.	7.2	122
39	SF3B1 Mutation Is an Independent Predictor of Parenchymal Iron Overload in Myelodysplastic Syndromes. <i>Blood</i> , 2015, 126, 1678-1678.	1.4	4
40	Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis: A Study of Agimm Group on 540 Patients. <i>Blood</i> , 2015, 126, 351-351.	1.4	1
41	Fusion Gene Detection Using Whole Transcriptome Analysis in Patients with Chronic Myeloproliferative Neoplasms and Secondary Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 4093-4093.	1.4	1
42	Whole Exome Sequencing Identifies Novel MPL and JAK2 Mutations in Triple Negative Myeloproliferative Neoplasms. <i>Blood</i> , 2015, 126, 606-606.	1.4	1
43	Whole Exome Sequencing Reveals Clonal Evolution of Myeloproliferative Neoplasms to Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 1626-1626.	1.4	0
44	Common Variation at 6q25.3 (TULP4) Influences Risk for Arterial Thrombosis in Myeloproliferative Neoplasms. <i>Blood</i> , 2015, 126, 4088-4088.	1.4	1
45	The Impact of Driver Mutations of JAK2, Calr, or MPL in Patients with Myelofibrosis Undergoing Hemopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 5405-5405.	1.4	0
46	Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2014, 89, 1107-1110.	4.1	47
47	Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. <i>Blood</i> , 2014, 124, 1062-1069.	1.4	340
48	A novel germline <i>JAK2</i> mutation in familial myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2014, 89, 117-118.	4.1	31
49	Cerebral venous thrombosis and myeloproliferative neoplasms: Results from two large databases. <i>Thrombosis Research</i> , 2014, 134, 41-43.	1.7	47
50	CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. <i>Blood</i> , 2014, 123, 2416-2419.	1.4	66
51	JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. <i>Blood</i> , 2014, 123, 1544-1551.	1.4	507
52	The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. <i>Leukemia</i> , 2014, 28, 1804-1810.	7.2	263
53	miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis. <i>Blood</i> , 2014, 124, e21-e32.	1.4	105
54	Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. <i>Blood</i> , 2014, 124, 1513-1521.	1.4	222

#	ARTICLE	IF	CITATIONS
55	Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin. <i>Blood</i> , 2014, 124, 3215-3215.	1.4	1
56	Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project. <i>Blood</i> , 2014, 124, 405-405.	1.4	47
57	Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms. <i>New England Journal of Medicine</i> , 2013, 369, 2379-2390.	27.0	1,698
58	Mutations and prognosis in primary myelofibrosis. <i>Leukemia</i> , 2013, 27, 1861-1869.	7.2	653
59	Efficacy of Ruxolitinib in Chronic Eosinophilic Leukemia Associated With a <i>PCM1-JAK2</i> Fusion Gene. <i>Journal of Clinical Oncology</i> , 2013, 31, e269-e271.	1.6	47
60	Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. <i>Blood</i> , 2013, 121, 4388-4395.	1.4	83
61	Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis. <i>Blood</i> , 2013, 122, 104-104.	1.4	3
62	Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. <i>PLoS ONE</i> , 2013, 8, e77819.	2.5	9
63	JAK2 (V617F)-Positive Essential Thrombocythemia and Polycythemia Vera Are Different Expressions Of a Genotypic/Phenotypic Continuum. <i>Blood</i> , 2013, 122, 1592-1592.	1.4	1
64	Integrative Analysis Of mRNA/miRNA Expression Profiles Identified JARID2 As a Shared Target Of Deregulated Mirnas In Primary Myelofibrosis. <i>Blood</i> , 2013, 122, 1600-1600.	1.4	0
65	Clinical significance of genetic aberrations in secondary acute myeloid leukemia. <i>American Journal of Hematology</i> , 2012, 87, 1010-1016.	4.1	67
66	COLD-PCR and Innovative Microarray Substrates for Detecting and Genotyping MPL Exon 10 W515 Substitutions. <i>Clinical Chemistry</i> , 2012, 58, 1692-1702.	3.2	9
67	JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2012, 87, 746-747.	4.1	8
68	The JAK2 V617F mutation in patients with cerebral venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 998-1003.	3.8	61
69	Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm. <i>American Journal of Hematology</i> , 2012, 87, 129-130.	4.1	1
70	Frequent deletions of <i>JARID2</i> in leukemic transformation of chronic myeloid malignancies. <i>American Journal of Hematology</i> , 2012, 87, 245-250.	4.1	107
71	Regulatory Mrna/Microrna Networks in CD34+ Cells From Primary Myelofibrosis.. <i>Blood</i> , 2012, 120, 2854-2854.	1.4	0
72	Clonal Analysis of SF3B1, JAK2 and MPL in Refractory Anemia with Ring Sideroblasts Associated with Marked Thrombocytosis. <i>Blood</i> , 2012, 120, 172-172.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Prognostic Impact of Mutations in a Large Series of Patients with Myelofibrosis. <i>Blood</i> , 2012, 120, 431-431.	1.4	19
74	Efficacy of Ruxolitinib in Chronic Eosinophilic Leukemia Associated with t(8;9)(p22;p24) and PCM1-JAK2 Fusion Gene.. <i>Blood</i> , 2012, 120, 2833-2833.	1.4	0
75	Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. <i>Blood</i> , 2011, 117, 2813-2816.	1.4	190
76	Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. <i>Haematologica</i> , 2011, 96, 454-458.	3.5	65
77	Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. <i>Haematologica</i> , 2011, 96, 167-170.	3.5	60
78	The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. <i>Haematologica</i> , 2011, 96, 367-374.	3.5	67
79	Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms. <i>Haematologica</i> , 2011, 96, 607-611.	3.5	64
80	Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. <i>Blood</i> , 2011, 118, 167-176.	1.4	153
81	Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm. <i>American Journal of Hematology</i> , 2011, 86, 974-979.	4.1	37
82	Distinct Genetic Lesions Drive Leukemogenesis in Secondary Acute Myeloid Leukemia,. <i>Blood</i> , 2011, 118, 3559-3559.	1.4	15
83	Validation of cytogenetic-based risk stratification in primary myelofibrosis. <i>Blood</i> , 2010, 115, 2719-2720.	1.4	6
84	A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. <i>Leukemia</i> , 2010, 24, 1574-1579.	7.2	321
85	Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. <i>Leukemia</i> , 2010, 24, 1290-1298.	7.2	135
86	Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. <i>Bone Marrow Transplantation</i> , 2010, 45, 798-800.	2.4	9
87	Chromosomal Aberration Network In Myeloproliferative Neoplasms. <i>Blood</i> , 2010, 116, 318-318.	1.4	3
88	Characterization of Chromosome 20q Deletions In Myeloproliferative Neoplasms Using Microarray Karyotyping and Next-Generation Sequencing. <i>Blood</i> , 2010, 116, 4099-4099.	1.4	65
89	Clinical Relevance of Bone Marrow Fibrosis and CD34-Positive Cell Clusters in Primary Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2009, 27, 754-762.	1.6	225
90	Blast phase of essential thrombocythemia: A single center study. <i>American Journal of Hematology</i> , 2009, 84, 641-644.	4.1	8

#	ARTICLE	IF	CITATIONS
91	Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. <i>Journal of Internal Medicine</i> , 2009, 265, 266-274.	6.0	26
92	The $\hat{\text{G}}\text{GCC}^{\text{TM}}$ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. <i>Leukemia</i> , 2009, 23, 1924-1926.	7.2	68
93	Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. <i>Haematologica</i> , 2009, 94, 38-45.	3.5	82
94	Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. <i>Blood</i> , 2009, 114, 3538-3545.	1.4	135
95	Deletions of the Transcription Factor Ikaros in Myeloproliferative Neoplasms at Transformation to Acute Myeloid Leukemia.. <i>Blood</i> , 2009, 114, 435-435.	1.4	7
96	Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations. <i>British Journal of Haematology</i> , 2008, 140, 162-168.	2.5	60
97	Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. <i>Blood</i> , 2008, 111, 1686-1689.	1.4	264
98	Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. <i>Haematologica</i> , 2008, 93, 1645-1651.	3.5	241
99	A dynamic prognostic model to predict survival in post- $\hat{\text{e}}$ polycythemia vera myelofibrosis. <i>Blood</i> , 2008, 111, 3383-3387.	1.4	108
100	Loss of Heterozygosity of Chromosome 1p34 and High Mutant Allele Burden in Patients with Post-Essential Thrombocythemia Myelofibrosis Carrying Somatic Mutations of MPL. <i>Blood</i> , 2008, 112, 176-176.	1.4	1
101	Familial Chronic Myeloproliferative Disorders: Clinical Phenotype and Evidence of Disease Anticipation. <i>Journal of Clinical Oncology</i> , 2007, 25, 5630-5635.	1.6	130
102	Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V&gt;F) mutation. <i>Blood</i> , 2007, 110, 485-489.	1.4	148
103	<i>JAK2</i> (V617F) mutation in healthy individuals. <i>British Journal of Haematology</i> , 2007, 136, 678-679.	2.5	40
104	Several Somatic Mutations of JAK2 Exon 12 Are Found in Patients with a JAK2 (V617F)-Negative Myeloproliferative Disorder That Is Mainly Characterized by Erythrocytosis.. <i>Blood</i> , 2007, 110, 263-263.	1.4	1
105	Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. <i>Blood</i> , 2006, 107, 3676-3682.	1.4	236
106	Cord blood in vitro expanded CD41+ cells: identification of novel components of megakaryocytopoiesis. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 848-860.	3.8	23
107	Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. <i>Leukemia</i> , 2006, 20, 549-555.	7.2	118
108	Rap2, but not Rap1 GTPase is expressed in human red blood cells and is involved in vesiculation. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2006, 1763, 330-335.	4.1	15

#	ARTICLE	IF	CITATIONS
109	JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. <i>Cancer</i> , 2006, 107, 2206-2211.	4.1	82
110	Sequential Evaluation of the Proportion of Granulocyte JAK2 (V617F) Mutant Alleles in Chronic Myeloproliferative Disorders.. <i>Blood</i> , 2006, 108, 2682-2682.	1.4	0
111	Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. <i>Blood</i> , 2005, 106, 3374-3376.	1.4	166
112	Genetic and clinical heterogeneity of ferroportin disease. <i>British Journal of Haematology</i> , 2005, 131, 663-670.	2.5	64
113	PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia. <i>Leukemia</i> , 2005, 19, 888-889.	7.2	8
114	Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders. <i>British Journal of Haematology</i> , 2004, 126, 650-656.	2.5	36
115	Haematological malignancies in relatives of patients affected with myeloproliferative neoplasms. <i>EJHaem</i> , 0, , .	1.0	0